BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 2005;48:372-380. [PMID: 16024941 DOI: 10.1159/000086064] [Cited by in Crossref: 219] [Cited by in F6Publishing: 196] [Article Influence: 13.7] [Reference Citation Analysis]
Number Citing Articles
1 Hu Z, Liu Y, Qiu L, Fan Z, Nie W, Liang S, Jin R. Quantitation of substitutions at amino acid 70 in hepatitis C virus genotype 1b. Virol J 2014;11:148. [PMID: 25128407 DOI: 10.1186/1743-422X-11-148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H. Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients. Gastroenterol Res Pract. 2014;2014:549709. [PMID: 25197269 DOI: 10.1155/2014/549709] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Shimada N, Toyoda H, Tsubota A, Ide T, Takaguchi K, Kato K, Kondoh M, Matsuyama K, Kumada T, Sata M. Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study. J Gastroenterol 2014;49:1485-94. [DOI: 10.1007/s00535-013-0918-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
4 Hayashi K, Katano Y, Masuda H, Ishizu Y, Kuzuya T, Honda T, Ishigami M, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H. Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B: PEG IFN for low HCV patients and ISDR and IL-28B. Hepatol Res 2013;43:580-8. [DOI: 10.1111/hepr.12005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Kawaoka T, Aikata H, Miyaki D, Murakami E, Azakami T, Takaki S, Nagaoki Y, Hashimoto Y, Katamura Y, Hiramatsu A. Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region. Hepatol Res. 2011;41:1126-1131. [PMID: 22032680 DOI: 10.1111/j.1872-034x.2011.00853.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Sezaki H, Suzuki F, Kawamura Y, Yatsuji H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Kumada H. Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load. Hepatol Res 2007;37:787-92. [PMID: 17573943 DOI: 10.1111/j.1872-034X.2007.00132.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
7 Ninomiya M, Ueno Y, Funayama R, Nagashima T, Nishida Y, Kondo Y, Inoue J, Kakazu E, Kimura O, Nakayama K. Use of illumina deep sequencing technology to differentiate hepatitis C virus variants. J Clin Microbiol. 2012;50:857-866. [PMID: 22205816 DOI: 10.1128/jcm.05715-11] [Cited by in Crossref: 40] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
8 Kumthip K, Pantip C, Chusri P, Thongsawat S, O’Brien A, Nelson KE, Maneekarn N. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy. J Viral Hepat. 2011;18:e117-e125. [PMID: 20955493 DOI: 10.1111/j.1365-2893.2010.01379.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
9 Kumthip K, Maneekarn N. The role of HCV proteins on treatment outcomes. Virol J 2015;12:217. [PMID: 26666318 DOI: 10.1186/s12985-015-0450-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
10 Inokuchi M, Ito T, Nozawa H, Miyashita M, Morikawa K, Uchikoshi M, Shimozuma Y, Arai J, Shimazaki T, Hiroishi K, Imawari M. Lymphotropic hepatitis C virus has an interferon-resistant phenotype. J Viral Hepat 2012;19:254-62. [PMID: 22404723 DOI: 10.1111/j.1365-2893.2011.01541.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
11 Jahan S, Khaliq S, Ijaz B, Ahmad W, Hassan S. Role of HCV Core gene of genotype 1a and 3a and host gene Cox-2 in HCV-induced pathogenesis. Virol J. 2011;8:155. [PMID: 21457561 DOI: 10.1186/1743-422x-8-155] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
12 Toyoda H, Kumada T. Favorable association between genetic polymorphisms near the IL28B gene and hepatic steatosis: direct or indirect? J Hepatol. 2012;56:738-79; author reply 739. [PMID: 22340673 DOI: 10.1016/j.jhep.2011.07.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
13 Furui Y, Hoshi Y, Murata K, Ito K, Suzuki K, Uchida S, Satake M, Mizokami M, Tadokoro K. Prevalence of amino acid mutation in hepatitis C virus core region among Japanese volunteer blood donors. J Med Virol. 2011;83:1924-1929. [PMID: 21915867 DOI: 10.1002/jmv.22216] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
14 Wada Y, Tamai H, Kawashima A, Shingaki N, Mori Y, Kawaguchi M, Moribata K, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M. Prediction of a null response to pegylated interferon α-2b plus ribavirin in patients with high viral load genotype 1b hepatitis C. Gut Liver 2014;8:421-7. [PMID: 25071908 DOI: 10.5009/gnl.2014.8.4.421] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Kawashima H, Ishikawa T, Tachi Y, Hattori M, Katano Y, Goto H, Hirooka Y. Comparison of direct sequencing and Invader assay for Y93H mutation and response to interferon-free therapy in hepatitis C virus genotype 1b: Y93H mutations in hepatitis C virus. Journal of Gastroenterology and Hepatology 2018;33:249-55. [DOI: 10.1111/jgh.13809] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
16 Sohda T, Yamauchi E, Anan A, Yokoyama K, Fukunaga A, Yamauchi R, Fukuda S, Takata K, Tanaka T, Hanano T, Kitamura Y, Morihara D, Takeyama Y, Irie M, Shakado S, Sakisaka S. Non-response to daclatasvir and asunaprevir therapy in patients co-infected with hepatitis C virus genotypes 1 and 2. Hepatol Res 2017;47:364-7. [PMID: 27260815 DOI: 10.1111/hepr.12758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
17 Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol. 2009;81:452-458. [PMID: 19152407 DOI: 10.1002/jmv.21400] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
18 Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol. 2007;79:1686-1695. [PMID: 17854035 DOI: 10.1002/jmv.20979] [Cited by in Crossref: 83] [Cited by in F6Publishing: 75] [Article Influence: 5.9] [Reference Citation Analysis]
19 Quiles-Pérez R, Muñoz-de-Rueda P, Maldonado AM, Martín-Álvarez A, Quer J, Salmerón J. Effects of ribavirin monotherapy on the viral population in patients with chronic hepatitis C genotype 1: direct sequencing and pyrosequencing of the HCV regions. J Med Virol 2014;86:1886-97. [PMID: 25091333 DOI: 10.1002/jmv.24035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
20 Funaoka Y, Sakamoto N, Suda G, Itsui Y, Nakagawa M, Kakinuma S, Watanabe T, Mishima K, Ueyama M, Onozuka I, Nitta S, Kitazume A, Kiyohashi K, Murakawa M, Azuma S, Tsuchiya K, Watanabe M. Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91. J Virol 2011;85:5986-94. [PMID: 21490101 DOI: 10.1128/JVI.02583-10] [Cited by in Crossref: 44] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
21 Kurbanov F, Tanaka Y, Chub E, Maruyama I, Azlarova A, Kamitsukasa H, Ohno T, Bonetto S, Moreau I, Fanning LJ, Legrand-Abravanel F, Izopet J, Naoumov N, Shimada T, Netesov S, Mizokami M. Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1_2k/1b. J Infect Dis 2008;198:1448-56. [PMID: 18928375 DOI: 10.1086/592757] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
22 Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Yatsuhashi H, Izumi N. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. J Gastroenterol 2011;46:401-9. [PMID: 20830599 DOI: 10.1007/s00535-010-0322-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
23 Dayyeh BK, Gupta N, Sherman KE, de Bakker PI, Chung RT; Aids Clinical Trials Group A5178 Study Team. IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy. PLoS One 2011;6:e25753. [PMID: 22003405 DOI: 10.1371/journal.pone.0025753] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
24 Takita M, Hagiwara S, Arizumi T, Hayaishi S, Ueda T, Kitai S, Yada N, Inoue T, Minami Y, Chung H, Ueshima K, Sakurai T, Kudo M. Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy. Digestion 2011;84 Suppl 1:56-61. [PMID: 22156487 DOI: 10.1159/000333215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
25 Morihara D, Watanabe H, Takata K, Iwashita H, Tsuchiya N, Kunimoto H, Kuno S, Fukunaga A, Yotsumoto K, Tanaka T, Sakurai K, Hirano G, Yokoyama K, Nishizawa S, Yoshikane M, Anan A, Takeyama Y, Kitamura Y, Iwata K, Irie M, Shakado S, Sohda T, Sakisaka S. Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate. Eur J Gastroenterol Hepatol 2015;27:55-64. [PMID: 25370853 DOI: 10.1097/MEG.0000000000000208] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
26 El-Shamy A, Kim SR, Ide YH, Sasase N, Imoto S, Deng L, Shoji I, Hotta H. Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy. Intervirology. 2012;55:1-11. [PMID: 21293098 DOI: 10.1159/000322219] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
27 KayvanJoo AH, Ebrahimi M, Haqshenas G. Prediction of hepatitis C virus interferon/ribavirin therapy outcome based on viral nucleotide attributes using machine learning algorithms. BMC Res Notes 2014;7:565. [PMID: 25150834 DOI: 10.1186/1756-0500-7-565] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
28 Hikita H, Enooku K, Satoh Y, Yoshida H, Nakagawa H, Masuzaki R, Tateishi R, Soroida Y, Sato M, Suzuki A, Gotoh H, Iwai T, Yokota H, Koike K, Yatomi Y, Ikeda H. Perihepatic lymph node enlargement is a negative predictor for sustained responses to pegylated interferon-α and ribavirin therapy for Japanese patients infected with hepatitis C virus genotype 1. Hepatol Res 2013;43:1005-12. [PMID: 23356977 DOI: 10.1111/hepr.12061] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Ueda Y, Kaido T, Ogura Y, Ogawa K, Yoshizawa A, Hata K, Fujimoto Y, Miyagawa-Hayashino A, Haga H, Marusawa H, Teramukai S, Uemoto S, Chiba T. Pretransplant serum hepatitis C virus RNA levels predict response to antiviral treatment after living donor liver transplantation. PLoS One 2013;8:e58380. [PMID: 23505497 DOI: 10.1371/journal.pone.0058380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology. 2007;50:361-368. [PMID: 17728547 DOI: 10.1159/000107707] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
31 Saludes Montoro V, Ausina Ruiz V, Martró Català E. [Current options for predicting therapeutic response in chronically infected patients with hepatitis C virus genotype 1]. Enferm Infecc Microbiol Clin 2011;29 Suppl 5:51-8. [PMID: 22305670 DOI: 10.1016/S0213-005X(11)70044-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. J Med Virol. 2010;82:575-582. [PMID: 20166188 DOI: 10.1002/jmv.21741] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
33 Akuta N, Sezaki H, Suzuki F, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y. Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. J Med Virol. 2016;88:506-511. [PMID: 26292191 DOI: 10.1002/jmv.24360] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
34 Tang X, Wagoner J, Negash A, Austin M, McLauchlan J, Hahn YS, Rosen HR, Polyak SJ. Functional characterization of core genes from patients with acute hepatitis C virus infection. J Infect Dis 2010;201:912-22. [PMID: 20170366 DOI: 10.1086/650699] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
35 Tamai H, Ida Y, Kawashima A, Shingaki N, Shimizu R, Moribata K, Nasu T, Maekita T, Iguchi M, Kato J, Nakao T, Kitano M. Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus. Gut Liver 2017;11:551-8. [PMID: 28506030 DOI: 10.5009/gnl16525] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Liang CM, Hu TH, Lu SN, Hung CH, Huang CM, Wang JH, Yen YH, Chen CH, Chang KC, Tsai MC. Role of hepatitis C virus substitutions and interleukin-28B polymorphism on response to peginterferon plus ribavirin in a prospective study of response-guided therapy. J Viral Hepat. 2013;20:761-769. [PMID: 24168255 DOI: 10.1111/jvh.12097] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
37 Nishiguchi S, Enomoto H, Aizawa N, Nishikawa H, Osaki Y, Tsuda Y, Higuchi K, Okazaki K, Seki T, Kim SR, Hongo Y, Jyomura H, Nishida N, Kudo M. Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study. J Gastroenterol 2014;49:492-501. [PMID: 23543311 DOI: 10.1007/s00535-013-0785-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
38 Uto H, Mawatari S, Kumagai K, Ido A, Tsubouchi H. Clinical features of hepatitis C virus carriers with persistently normal alanine aminotransferase levels. Hepat Mon 2012;12:77-84. [PMID: 22509183 DOI: 10.5812/hepatmon.829] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
39 Sakamoto N, Tanaka Y, Nakagawa M, Yatsuhashi H, Nishiguchi S, Enomoto N, Azuma S, Nishimura-sakurai Y, Kakinuma S, Nishida N, Tokunaga K, Honda M, Ito K, Mizokami M, Watanabe M. ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C: ITPA gene variant against anemia. Hepatology Research 2010;40:1063-71. [DOI: 10.1111/j.1872-034x.2010.00741.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
40 Kondo C, Atsukawa M, Tsubota A, Itokawa N, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Sakamoto C. An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin: PEG- IFN/ribavirin/fluvastatin therapy. Journal of Viral Hepatitis 2012;19:615-22. [DOI: 10.1111/j.1365-2893.2011.01584.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
41 Harada N, Tamura S, Sugawara Y, Togashi J, Ishizawa T, Kaneko J, Aoki T, Sakamoto Y, Hasegawa K, Tanaka T, Yamashiki N, Kokudo N. Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C. PLoS One 2014;9:e90462. [PMID: 24599320 DOI: 10.1371/journal.pone.0090462] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
42 Saludes V, Bracho MA, Valero O, Ardèvol M, Planas R, González-Candelas F, Ausina V, Martró E. Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors. PLoS One 2010;5:e14132. [PMID: 21152430 DOI: 10.1371/journal.pone.0014132] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
43 Tasaka-Fujita M, Sugiyama N, Kang W, Masaki T, Murayama A, Yamada N, Sugiyama R, Tsukuda S, Watashi K, Asahina Y, Sakamoto N, Wakita T, Shin EC, Kato T. Amino Acid Polymorphisms in Hepatitis C Virus Core Affect Infectious Virus Production and Major Histocompatibility Complex Class I Molecule Expression. Sci Rep 2015;5:13994. [PMID: 26365522 DOI: 10.1038/srep13994] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
44 Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, Sakamoto M. Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy. Hepatol Int. 2011;5:789-799. [PMID: 21484117 DOI: 10.1007/s12072-011-9267-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
45 Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol. 2012;57:1110-1125. [PMID: 22659520 DOI: 10.1016/j.jhep.2012.05.016] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 8.3] [Reference Citation Analysis]
46 Aizawa N, Enomoto H, Takashima T, Sakai Y, Iwata K, Ikeda N, Tanaka H, Iwata Y, Saito M, Imanishi H. Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol. 2014;49:1253-1263. [PMID: 24065124 DOI: 10.1007/s00535-013-0884-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
47 Matsuura K, Watanabe T, Iijima S, Murakami S, Fujiwara K, Orito E, Iio E, Endo M, Kusakabe A, Shinkai N. Serum interferon-gamma-inducible protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C. Hepatol Res. 2014;44:1208-1216. [PMID: 24372894 DOI: 10.1111/hepr.12294] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
48 Mukaide M, Sugiyama M, Korenaga M, Murata K, Kanto T, Masaki N, Mizokami M. High-throughput and sensitive next-generation droplet digital PCR assay for the quantitation of the hepatitis C virus mutation at core amino acid 70. J Virol Methods. 2014;207:169-177. [PMID: 25019167 DOI: 10.1016/j.jviromet.2014.07.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
49 Yoneda S, Umemura T, Katsuyama Y, Kamijo A, Joshita S, Komatsu M, Ichijo T, Matsumoto A, Yoshizawa K, Ota M, Tanaka E; Nagano Interferon Treatment Research Group. Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients. J Infect Dis 2011;203:1087-95. [PMID: 21398397 DOI: 10.1093/infdis/jiq165] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
50 Uchida Y, Kouyama J, Naiki K, Sugawara K, Ando S, Nakao M, Motoya D, Inao M, Imai Y, Nakayama N, Mochida S. Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing. J Gastroenterol 2016;51:260-70. [DOI: 10.1007/s00535-015-1106-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
51 Petruzziello A. Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma. Open Virol J. 2018;12:26-32. [PMID: 29541276 DOI: 10.2174/1874357901812010026] [Cited by in Crossref: 84] [Cited by in F6Publishing: 86] [Article Influence: 28.0] [Reference Citation Analysis]
52 Kan T, Hashimoto S, Kawabe N, Murao M, Nakano T, Shimazaki H, Nakaoka K, Ohki M, Takagawa Y, Kurashita T, Takamura T, Yoshioka K. The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay. J Gastroenterol 2016;51:63-70. [DOI: 10.1007/s00535-015-1080-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
53 Ikeda F, Dansako H, Nishimura G, Mori K, Kawai Y, Ariumi Y, Miyake Y, Takaki A, Nouso K, Iwasaki Y. Amino acid substitutions of hepatitis C virus core protein are not associated with intracellular antiviral response to interferon-α in vitro. Liver Int. 2010;30:1324-1331. [PMID: 20602680 DOI: 10.1111/j.1478-3231.2010.02299.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
54 Glisic S, Veljkovic N, Jovanovic Cupic S, Vasiljevic N, Prljic J, Gemovic B, Perovic V, Veljkovic V. Assessment of Hepatitis C Virus Protein Sequences with Regard to Interferon/Ribavirin Combination Therapy Response in Patients with HCV Genotype 1b. Protein J 2012;31:129-36. [DOI: 10.1007/s10930-011-9381-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
55 Li HC, Ma HC, Yang CH, Lo SY. Production and pathogenicity of hepatitis C virus core gene products. World J Gastroenterol 2014; 20(23): 7104-7122 [PMID: 24966583 DOI: 10.3748/wjg.v20.i23.7104] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
56 Khaliq S, Latief N, Jahan S. Role of different regions of the hepatitis C virus genome in the therapeutic response to interferon-based treatment. Arch Virol. 2014;159:1-15. [PMID: 23851652 DOI: 10.1007/s00705-013-1780-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
57 Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, Tanaka E, Onji M, Toyota J, Chayama K. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol. 2009;44:952-963. [PMID: 19517057 DOI: 10.1007/s00535-009-0087-x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 5.1] [Reference Citation Analysis]
58 Nagao Y, Sata M. A retrospective case-control study of hepatitis C virus infection and oral lichen planus in Japan: association study with mutations in the core and NS5A region of hepatitis C virus. BMC Gastroenterol 2012;12:31. [PMID: 22490000 DOI: 10.1186/1471-230X-12-31] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
59 Yamagiwa S, Ishikawa T, Waguri N, Sugitani S, Kamimura K, Tsuchiya A, Takamura M, Kawai H, Terai S. Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C. Int J Med Sci 2017;14:403-11. [PMID: 28539815 DOI: 10.7150/ijms.18784] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
60 Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Fukuda K, Mita E, Haruna Y, Inoue A, Imai Y, Hosui A, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin. J Med Virol 2011;83:419-27. [DOI: 10.1002/jmv.21975] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
61 Akuta N, Suzuki F, Kobayashi M, Sezaki H, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H. Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA. J Clin Microbiol 2015;53:3039-41. [PMID: 26135874 DOI: 10.1128/JCM.01457-15] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
62 Hiraga N, Abe H, Imamura M, Tsuge M, Takahashi S, Hayes CN, Ochi H, Tateno C, Yoshizato K, Nakamura Y. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Hepatology. 2011;54:764-771. [PMID: 21618576 DOI: 10.1002/hep.24453] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
63 Takashima T, Enomoto H, Ninomiya T, Kim SR, Okushin H, Sugano M, Imoto S, Yano Y, Ooka T, Seo Y, Kasugai H, Muramatsu A, Jomura H, Shimomura S, Shindo M, Nakamura H, Aizawa N, Iwata Y, Saito M, Imanishi H, Iijma H, Nishiguchi S. Hepatitis C virus relapse was suppressed by long-term self-injection of low-dose interferon in patients with chronic hepatitis C after pegylated interferon plus ribavirin treatment. Hepatol Res 2014;44:597-607. [PMID: 23639109 DOI: 10.1111/hepr.12153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
64 Ishii K, Shinohara M, Kogame M, Shiratori M, Higami K, Kanayama K, Shiozawa K, Wakui N, Nagai H, Watanabe M, Sumino Y. Effects of mutation number in interferon sensitivity determining region on peripheral blood CD4(+) T cell subsets (Th1, Th2) in chronic hepatitis C patients with hepatitis C virus genotype 1b and high viral load. Hepatol Int 2012;6:468-74. [PMID: 21818686 DOI: 10.1007/s12072-011-9305-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
65 Seko Y, Akuta N, Suzuki F, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S. Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy. Intervirology. 2013;56:13-21. [PMID: 22907167 DOI: 10.1159/000339993] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
66 Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M. Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment. Intervirology. 2012;55:417-425. [PMID: 21325786 DOI: 10.1159/000323526] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
67 Rayan Da'as S, Azzeh M. Subgenotyping and genetic variability of hepatitis C virus in Palestine. PLoS One 2019;14:e0222799. [PMID: 31589628 DOI: 10.1371/journal.pone.0222799] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Toyoda H, Kumada T, Kaneoka Y, Maeda A. Amino Acid Substitutions in the Hepatitis C Virus Core Region Are Associated With Postoperative Recurrence and Survival of Patients With HCV Genotype 1b-Associated Hepatocellular Carcinoma. Annals of Surgery 2011;254:326-32. [DOI: 10.1097/sla.0b013e3182263b8e] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
69 Alhamlan FS, Al-Ahdal MN, Khalaf NZ, Abdo AA, Sanai FM, Al-Ashgar HI, ElHefnawi M, Zaid A, Al-Qahtani AA. Genetic variability of the core protein in hepatitis C virus genotype 4 in Saudi Arabian patients and its implication on pegylated interferon and ribavirin therapy. J Transl Med 2014;12:91. [PMID: 24708767 DOI: 10.1186/1479-5876-12-91] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
70 Akuta N, Suzuki F, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Saitoh S, Kobayashi M, Ikeda K, Kumada H. Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b. J Med Virol 2015;87:609-18. [PMID: 25655809 DOI: 10.1002/jmv.24113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
71 Jaspe RC, Sulbarán YF, Sulbarán MZ, Loureiro CL, Rangel HR, Pujol FH. Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates. Virol J 2012;9:214. [PMID: 22995142 DOI: 10.1186/1743-422X-9-214] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
72 Tanaka Y, Nishida N, Sugiyama M, Tokunaga K, Mizokami M. lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C. Hepatol Res. 2010;40:449-460. [PMID: 20546329 DOI: 10.1111/j.1872-034X.2010.00671.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
73 Hayashi K, Ishigami M, Yasuda S, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Hirooka Y, Goto H. Occurrence of late relapse of hepatitis C virus confirmed by molecular analysis after sustained virologic response to interferon-ribavirin-based therapy. Hepatol Res 2018;48:E78-86. [PMID: 28643404 DOI: 10.1111/hepr.12929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
74 Kadjbaf D, Keshvari M, Alavian SM, Pouryasin A, Behnava B, Salimi S, Mehrnoush L, Karimi Elizee P, Sharafi H. The Prevalence of Hepatitis C Virus Core Amino Acid 70 Substitution and Genotypes of Polymorphisms Near the IFNL3 Gene in Iranian Patients With Chronic Hepatitis C. Hepat Mon 2016;16:e37011. [PMID: 27630727 DOI: 10.5812/hepatmon.37011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
75 Chayama K, Hayes CN, Ohishi W, Kawakami Y. Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. J Gastroenterol. 2013;48:1-12. [PMID: 23188091 DOI: 10.1007/s00535-012-0714-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
76 Honda A, Matsuzaki Y. Cholesterol and chronic hepatitis C virus infection. Hepatol Res 2011;41:697-710. [PMID: 21682830 DOI: 10.1111/j.1872-034X.2011.00838.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
77 Toyoda H, Kumada T, Hayashi K, Honda T, Katano Y, Goto H, Kawaguchi T, Murakami Y, Matsuda F. Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene. J Med Virol 2011;83:1559-64. [DOI: 10.1002/jmv.22145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
78 Azakami T, Hayes CN, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Tsuge M. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. J Med Virol. 2011;83:1048-1057. [PMID: 21503919 DOI: 10.1002/jmv.22069] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
79 Ueda T, Tsuchiya K, Hashimoto S, Inoue T, Enomoto N, Inao M, Tanaka A, Kaito M, Imazeki F, Nishiguchi S, Mochida S, Yokosuka O, Yatsuhashi H, Izumi N, Kudo M; RETRY Study Group. Retreatment with peginterferon α-2a + ribavirin in patients who failed previous peginterferon α-2b + ribavirin combination therapy. Dig Dis 2012;30:554-60. [PMID: 23258094 DOI: 10.1159/000343064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
80 Ohnishi M, Tsuge M, Kohno T, Zhang Y, Abe H, Hyogo H, Kimura Y, Miki D, Hiraga N, Imamura M. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients. J Gastroenterol. 2012;47:834-844. [PMID: 22350701 DOI: 10.1007/s00535-012-0550-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
81 Abdallah F, Mohamed G, Ibrahim M, El Tarabily M. Effectiveness of Sofosbuvir, Ribavirin and PEG-IFNα-2a in the Treatment of Naïve Egyptian Patients With Chronic Hepatitis C Virus Genotype 4. Am J Med Sci 2018;355:456-66. [PMID: 29753376 DOI: 10.1016/j.amjms.2017.12.016] [Reference Citation Analysis]
82 Kim DW, Lee SA, Kim H, Won YS, Kim BJ. Naturally occurring mutations in the nonstructural region 5B of hepatitis C virus (HCV) from treatment-naïve Korean patients chronically infected with HCV genotype 1b. PLoS One. 2014;9:e87773. [PMID: 24489961 DOI: 10.1371/journal.pone.0087773] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
83 Masaki N, Sugiyama M, Shimada N, Tanaka Y, Nakamuta M, Izumi N, Watanabe S, Tsubota A, Komatsu M, Masaki T, Enomoto N, Yoneda M, Murata K, Ito K, Koike K, Mizokami M. Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C. J Gastroenterol Hepatol 2014;29:1996-2005. [PMID: 24910341 DOI: 10.1111/jgh.12646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
84 Nakagawa M, Sakamoto N, Ueyama M, Mogushi K, Nagaie S, Itsui Y, Azuma S, Kakinuma S, Tanaka H, Enomoto N, Watanabe M. Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection. J Gastroenterol 2010;45:656-65. [DOI: 10.1007/s00535-009-0195-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
85 Toyoda H, Kumada T, Shimada N, Takaguchi K, Ide T, Sata M, Ginba H, Matsuyama K, Izumi N. Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study. J Med Virol 2013;85:65-70. [PMID: 23154876 DOI: 10.1002/jmv.23428] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
86 Alestig E, Arnholm B, Eilard A, Lagging M, Nilsson S, Norkrans G, Wahlberg T, Wejstål R, Westin J, Lindh M. Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection. BMC Infect Dis 2011;11:124. [PMID: 21569441 DOI: 10.1186/1471-2334-11-124] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
87 Sedeno-Monge V, Vallejo-Ruiz V, Sosa-Jurado F, Santos-Lopez G. Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma. J Biosci 2017;42:509-21. [PMID: 29358564 DOI: 10.1007/s12038-017-9695-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
88 Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. J Med Virol 2011;83:1016-22. [DOI: 10.1002/jmv.22094] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
89 Gottwein JM, Jensen TB, Mathiesen CK, Meuleman P, Serre SB, Lademann JB, Ghanem L, Scheel TK, Leroux-Roels G, Bukh J. Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A. J Virol 2011;85:8913-28. [PMID: 21697486 DOI: 10.1128/JVI.00049-11] [Cited by in Crossref: 64] [Cited by in F6Publishing: 41] [Article Influence: 6.4] [Reference Citation Analysis]
90 El-Shamy A, Shindo M, Shoji I, Deng L, Okuno T, Hotta H. Polymorphisms of the core, NS3, and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma. Hepatology. 2013;58:555-563. [PMID: 23281009 DOI: 10.1002/hep.26205] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
91 Alhamlan FS, Al-Ahdal MN, Khalaf NZ, Abdo AA, Sanai FM, Al-Ashgar HI, Elhefnawi M, Zaid A, Al-Qahtani AA. Hepatitis C virus genotype 1: how genetic variability of the core protein affects the response to pegylated-interferon and ribavirin therapy. J Med Virol. 2014;86:224-234. [PMID: 24166351 DOI: 10.1002/jmv.23823] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
92 Chu PS, Ebinuma H, Nakamoto N, Sugiyama K, Usui S, Wakayama Y, Taniki N, Yamaguchi A, Shiba S, Yamagishi Y, Wakita T, Hibi T, Saito H, Kanai T. Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C. PLoS One 2015;10:e0125664. [PMID: 25965701 DOI: 10.1371/journal.pone.0125664] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
93 Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010;52:421-429. [PMID: 20648473 DOI: 10.1002/hep.23690] [Cited by in Crossref: 209] [Cited by in F6Publishing: 189] [Article Influence: 19.0] [Reference Citation Analysis]
94 Hu Z, Muroyama R, Kowatari N, Chang J, Omata M, Kato N. Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinoma. Cancer Sci. 2009;100:2465-2468. [PMID: 20175782 DOI: 10.1111/j.1349-7006.2009.01338.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
95 Di Lello FA, Mira JA, Neukam K, Parra-Sánchez M, Guelfo JR, Cifuentes C, Macías J, Palomares JC, Gómez-Mateos J, Pineda JA, Real LM. Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection. Arch Virol 2014;159:3345-51. [PMID: 25161034 DOI: 10.1007/s00705-014-2209-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
96 Yamagiwa Y, Asano M, Kawasaki Y, Korenaga M, Murata K, Kanto T, Mizokami M, Masaki N. Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy. Cytokine 2016;88:29-36. [PMID: 27541605 DOI: 10.1016/j.cyto.2016.07.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
97 Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy. J Med Virol 2008;80:1363-9. [PMID: 18551610 DOI: 10.1002/jmv.21224] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
98 Mori KI, Matsumoto A, Maki N, Ichikawa Y, Tanaka E, Yagi S. Production of infectious HCV genotype 1b virus in cell culture using a novel Set of adaptive mutations. BMC Microbiol 2016;16:224. [PMID: 27678340 DOI: 10.1186/s12866-016-0846-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
99 Chayama K, Hayes CN. Hepatitis C virus: How genetic variability affects pathobiology of disease. J Gastroenterol Hepatol. 2011;26 Suppl 1:83-95. [PMID: 21199518 DOI: 10.1111/j.1440-1746.2010.06550.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]
100 Enomoto H, Nishiguchi S. Factors associated with the response to interferon-based antiviral therapies for chronic hepatitis C. World J Hepatol 2015; 7(26): 2681-2687 [PMID: 26609345 DOI: 10.4254/wjh.v7.i26.2681] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
101 Resham S, Manzoor S, Imran M, Saalim M, Naseem S, Azam S. Interleukin- 28B: a prognostic marker in interferon based therapy of chronic HCV patients of the Pakistan with variable treatment response. APMIS. 2015;123:765-771. [PMID: 26177560 DOI: 10.1111/apm.12414] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
102 Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S. Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. Intervirology. 2012;55:231-241. [PMID: 21734353 DOI: 10.1159/000328327] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
103 Tachi Y, Katano Y, Honda T, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, Samejima Y, Goto H. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. Liver International 2010;30:554-9. [DOI: 10.1111/j.1478-3231.2009.02164.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
104 Saludes V, Bascuñana E, Jordana-Lluch E, Casanovas S, Ardèvol M, Soler E, Planas R, Ausina V, Martró E. Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients. PLoS One 2013;8:e72600. [PMID: 24015264 DOI: 10.1371/journal.pone.0072600] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
105 Fujii H, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Nakamura H, Yasui K, Minami M, Tanaka S, Ishikawa H, Kimura H, Takami S, Nagao Y, Shima T, Itoh Y. Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions. World J Hepatol 2017; 9(25): 1064-1072 [PMID: 28951778 DOI: 10.4254/wjh.v9.i25.1064] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
106 Tsubota A, Shimada N, Atsukawa M, Abe H, Kato K, Ika M, Matsudaira H, Nagatsuma K, Matsuura T, Aizawa Y. Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b. J Gastroenterol Hepatol 2014;29:144-50. [PMID: 24117654 DOI: 10.1111/jgh.12402] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
107 Namiki I, Nishiguchi S, Hino K, Suzuki F, Kumada H, Itoh Y, Asahina Y, Tamori A, Hiramatsu N, Hayashi N. Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:347-368. [PMID: 20394674 DOI: 10.1111/j.1872-034x.2010.00642.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
108 Komase K, Maekawa S, Miura M, Sueki R, Kadokura M, Shindo H, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C: RANTES and PEG IFN/RBV response in HCV. Hepatol Res 2013;43:865-75. [DOI: 10.1111/hepr.12032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
109 Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Yoshioka K, Toyoda H, Kumada T, Goto H. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy: SNP of IL28B, HCV core, NS5A genotype 1b and Peg-IFN+RBV. Liver International 2011;31:1359-65. [DOI: 10.1111/j.1478-3231.2011.02571.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
110 Shimada N, Tsubota A, Atsukawa M, Abe H, Ide T, Takaguchi K, Chuganji Y, Toyoda H, Yoshizawa K, Ika M, Sato Y, Kato K, Kumada T, Sakamoto C, Aizawa Y, Sata M. A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study: 48-week TVR-based therapy for non-responders. Hepatol Res 2014;44:E386-96. [DOI: 10.1111/hepr.12323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
111 Tamai H, Shingaki N, Shiraki T, Tukuda H, Mori Y, Moribata K, Enomoto S, Deguchi H, Ueda K, Inoue I. Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation. Hepatol Res. 2011;41:1137-1144. [PMID: 21951330 DOI: 10.1111/j.1872-034x.2011.00879.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
112 El-Shamy A, Shoji I, El-Akel W, Bilasy SE, Deng L, El-Raziky M, Jiang DP, Esmat G, Hotta H. NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. J Clin Microbiol. 2012;50:3886-3892. [PMID: 22993188 DOI: 10.1128/jcm.02109-12] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
113 Itoh Y, Nishimura T, Hashimoto H, Yamaguchi K, Niimi T, Yokomizo C, Fujii H, Minami M, Yasui K, Mitsuyoshi H, Okanoue T, Takehara T, Hiasa Y, Onji M, Yoshikawa T. Simple formula to predict response to peginterferon alpha2b and ribavirin combination therapy in genotype 1 chronic hepatitis C patients with high viral loads. Hepatol Res 2011;41:126-32. [PMID: 21269382 DOI: 10.1111/j.1872-034X.2010.00750.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
114 Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis. Intervirology 2013;56:37-45. [PMID: 23037768 DOI: 10.1159/000342746] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
115 Hara T, Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Kumada H. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C. J Med Virol. 2013;85:1746-1753. [PMID: 23861088 DOI: 10.1002/jmv.23673] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
116 Utama A, Tania NP, Dhenni R, Gani RA, Hasan I, Sanityoso A, Lelosutan SA, Martamala R, Lesmana LA, Sulaiman A, Tai S. Genotype diversity of hepatitis C virus (HCV) in HCV-associated liver disease patients in Indonesia. Liver Int 2010;30:1152-60. [PMID: 20492518 DOI: 10.1111/j.1478-3231.2010.02280.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
117 Hayashi K, Katano Y, Ishizu Y, Kuzuya T, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I. Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness. J Gastroenterol Hepatol. 2015;30:178-183. [PMID: 24995561 DOI: 10.1111/jgh.12673] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
118 Khaliq S, Jahan S, Pervaiz A. Sequence variability of HCV Core region: Important predictors of HCV induced pathogenesis and viral production. Infection, Genetics and Evolution 2011;11:543-56. [DOI: 10.1016/j.meegid.2011.01.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
119 Brahim I, Ezzikouri S, Mtairag el M, Alaoui R, Nadir S, Pineau P, Benjelloun S. Amino acid substitutions in the Hepatitis C virus core region of genotype 1b in Moroccan patients. Infect Genet Evol 2013;14:102-4. [PMID: 23146829 DOI: 10.1016/j.meegid.2012.10.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
120 Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1. J Med Virol. 2013;85:1028-1036. [PMID: 23588728 DOI: 10.1002/jmv.23579] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
121 Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J Med Virol 2009;81:1032-9. [PMID: 19382270 DOI: 10.1002/jmv.21473] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
122 Akuta N, Suzuki F, Sezaki H, Kobayashi M, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H. Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance. J Clin Microbiol 2019;57:e01463-18. [PMID: 30381417 DOI: 10.1128/JCM.01463-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
123 Kobayashi M, Akuta N, Suzuki F, Hosaka T, Sezaki H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Mineta R, Iwasaki S, Miyakawa Y, Kumada H. Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. J Med Virol 2010;82:41-8. [DOI: 10.1002/jmv.21629] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
124 Yoneda S, Umemura T, Joshita S, Ichijo T, Matsumoto A, Yoshizawa K, Katsuyama Y, Ota M, Tanaka E. Serum chemokine levels are associated with the outcome of pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Hepatol Res. 2011;41:587-593. [PMID: 21504519 DOI: 10.1111/j.1872-034x.2011.00802.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
125 Sato M, Maekawa S, Komatsu N, Tatsumi A, Miura M, Muraoka M, Suzuki Y, Amemiya F, Takano S, Fukasawa M, Nakayama Y, Yamaguchi T, Uetake T, Inoue T, Sato T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus. J Virol. 2015;89:6105-6116. [PMID: 25810555 DOI: 10.1128/jvi.03127-14] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
126 Yoshimi S, Ochi H, Murakami E, Uchida T, Kan H, Akamatsu S, Hayes CN, Abe H, Miki D, Hiraga N, Imamura M, Aikata H, Chayama K. Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay. PLoS One. 2015;10:e0130022. [PMID: 26083687 DOI: 10.1371/journal.pone.0130022] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
127 Schweitzer CJ, Liang TJ. Impact of host and virus genome variability on HCV replication and response to interferon. Curr Opin Virol 2013;3:501-7. [PMID: 23835049 DOI: 10.1016/j.coviro.2013.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
128 Kim SR, El-Shamy A, Imoto S, Kim KI, Ide YH, Deng L, Shoji I, Tanaka Y, Hasegawa Y, Ota M. Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load. J Gastroenterol. 2012;47:1143-1151. [PMID: 22441534 DOI: 10.1007/s00535-012-0578-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
129 Miura M, Maekawa S, Sato M, Komatsu N, Tatsumi A, Takano S, Amemiya F, Nakayama Y, Inoue T, Sakamoto M. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res. 2014;44:E360-367. [PMID: 24612030 DOI: 10.1111/hepr.12316] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
130 Kawaoka T, Hiraga N, Takahashi S, Takaki S, Mitsui F, Tsuge M, Nagaoki Y, Kimura Y, Hashimoto Y, Katamura Y, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Aikata H, Tashiro H, Ohdan H, Chayama K. Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: Analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus. Scandinavian Journal of Gastroenterology 2010;45:1488-96. [DOI: 10.3109/00365521.2010.505657] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
131 Kanda T, Nakamoto S, Arai M, Miyamura T, Wu S, Fujiwara K, Yokosuka O. Natural interferon-beta plus ribavirin therapy led to sustained virological response after seven unsuccessful courses of anti-viral treatment in a chronic hepatitis C patient. Clin J Gastroenterol 2013;6:160-3. [DOI: 10.1007/s12328-013-0366-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
132 Uto H, Mawatari S, Kumagai K, Ido A, Tsubouchi H. Clinical Features of Hepatitis C Virus Carriers With Persistently normal Alanine Aminotransferase Levels. Hepat Mon 2012;12:77-84. [DOI: 10.5812/hepatmon.4851] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
133 Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. J Med Virol. 2012;84:1097-1105. [PMID: 22585728 DOI: 10.1002/jmv.23262] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
134 Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol. 2006;78:83-90. [PMID: 16299715 DOI: 10.1002/jmv.20507] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 5.3] [Reference Citation Analysis]
135 Serre SB, Krarup HB, Bukh J, Gottwein JM. Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance. J Virol 2013;87:12776-93. [PMID: 24049176 DOI: 10.1128/JVI.00901-13] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
136 Bokharaei-Salim F, Salehi-Vaziri M, Sadeghi F, Esghaei M, Monavari SH, Alavian SM, Fakhim S, Keyvani H. The Association of Substitutions in the Hepatitis C Virus Subtype 1b Core Gene and IL28B Polymorphisms With the Response to Peg-IFNα-2a/RBV Combination Therapy in Azerbaijani Patients. Hepat Mon 2016;16:e35597. [PMID: 27313635 DOI: 10.5812/hepatmon.35597] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
137 Doyle JS, Hellard ME, Thompson AJ. The role of viral and host genetics in natural history and treatment of chronic HCV infection. Best Pract Res Clin Gastroenterol. 2012;26:413-427. [PMID: 23199501 DOI: 10.1016/j.bpg.2012.09.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
138 Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Utility of detection of telaprevir-resistant variants for prediction of efficacy of treatment of hepatitis C virus genotype 1 infection. J Clin Microbiol 2014;52:193-200. [PMID: 24197875 DOI: 10.1128/JCM.02371-13] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
139 Maekawa S, Enomoto N. Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J Gastroenterol. 2009;44:1009-1015. [PMID: 19756352 DOI: 10.1007/s00535-009-0126-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
140 Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Tamori A, Nakagawa M, Izumi N. Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis. J Med Virol 2011;83:445-52. [PMID: 21264865 DOI: 10.1002/jmv.22005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
141 Yamada K, Ishigami M, Kuzuya T, Honda T, Hayashi K, Goto H. Associations between responses to interferon therapy and genetic variation in interleukin-28B and the core region of hepatitis C virus genotype 3a. J Med Virol 2015;87:1361-7. [PMID: 25907669 DOI: 10.1002/jmv.24084] [Reference Citation Analysis]
142 Sumida Y, Kanemasa K, Hara T, Inada Y, Sakai K, Imai S, Yoshida N, Yasui K, Itoh Y, Okanoue T, Yoshikawa T. Impact of amino acid substitutions in hepatitis C virus genotype 1b core region on liver steatosis and glucose tolerance in non-cirrhotic patients without overt diabetes. J Gastroenterol Hepatol 2011;26:836-42. [PMID: 21054524 DOI: 10.1111/j.1440-1746.2010.06568.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
143 Chayama K, Hayes CN, Abe H, Miki D, Ochi H, Karino Y, Toyota J, Nakamura Y, Kamatani N, Sezaki H. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis. 2011;204:84-93. [PMID: 21628662 DOI: 10.1093/infdis/jir210] [Cited by in Crossref: 98] [Cited by in F6Publishing: 89] [Article Influence: 9.8] [Reference Citation Analysis]
144 Editors of the Drafting Committee for Hepatitis Management Guidelines: The Japan Society of Hepatology. Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology. Hepatol Res. 2013;43:1-34. [PMID: 23332085 DOI: 10.1111/hepr.12020] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
145 Atsukawa M, Tsubota A, Shimada N, Abe H, Kondo C, Itokawa N, Nakagawa A, Iwakiri K, Kawamoto C, Aizawa Y. Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C. Dig Liver Dis. 2014;46:738-743. [PMID: 24880716 DOI: 10.1016/j.dld.2014.05.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
146 Fujii H, Itoh Y, Ohnishi N, Sakamoto M, Ohkawara T, Sawa Y, Nishida K, Nishimura T, Yamaguchi K, Yasui K, Minami M, Okanoue T, Ohkawara Y, Yoshikawa T. Relapse of hepatitis C in a pegylated-interferon-alpha-2b plus ribavirin-treated sustained virological responder. Hepatol Res 2010;40:654-60. [PMID: 20618461 DOI: 10.1111/j.1872-034X.2010.00641.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
147 Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Arase Y, Ikeda K, Kumada H. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology. 2007;46:1357-1364. [PMID: 17657816 DOI: 10.1002/hep.21836] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 6.6] [Reference Citation Analysis]
148 Perales C, Beach NM, Gallego I, Soria ME, Quer J, Esteban JI, Rice C, Domingo E, Sheldon J. Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype. J Virol. 2013;87:7593-7607. [PMID: 23637397 DOI: 10.1128/jvi.02824-12] [Cited by in Crossref: 61] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
149 Tsuge M, Fujimoto Y, Hiraga N, Zhang Y, Ohnishi M, Kohno T, Abe H, Miki D, Imamura M, Takahashi S. Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse. PLoS One. 2011;6:e23856. [PMID: 21886832 DOI: 10.1371/journal.pone.0023856] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
150 Ikeda H, Suzuki M, Okuse C, Yamada N, Okamoto M, Kobayashi M, Nagase Y, Takahashi H, Matsunaga K, Matsumoto N. Short-term prolongation of pegylated interferon and ribavirin therapy for genotype 1b chronic hepatitis C patients with early viral response. Hepatol Res. 2009;39:753-759. [PMID: 19467024 DOI: 10.1111/j.1872-034X.2009.00523.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
151 Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol. 2011;54:439-448. [PMID: 21129805 DOI: 10.1016/j.jhep.2010.07.037] [Cited by in Crossref: 92] [Cited by in F6Publishing: 83] [Article Influence: 8.4] [Reference Citation Analysis]
152 Suzuki F, Suzuki Y, Sezaki H, Akuta N, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Mineta R, Watahiki S, Kobayashi M, Nakayasu Y, Tsuda H, Aoki K, Yamada I, Kumada H. Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. Hepatol Res 2013;43:691-701. [PMID: 23190247 DOI: 10.1111/hepr.12009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
153 Kawaoka T, Hiraga N, Takahashi S, Takaki S, Tsuge M, Nagaoki Y, Hashimoto Y, Katamura Y, Miki D, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Aikata H, Ochi H, Tashiro H, Ohdan H, Chayama K. Achievement of Sustained Viral Response after Switching Treatment from Pegylated Interferon a-2b to a-2a and Ribavirin in Patients with Recurrence of Hepatitis C Virus Genotype 1 Infection after Liver Transplantation: A Case Report. Intervirology 2012;55:122-6. [DOI: 10.1159/000328661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
154 Uemura H, Uchida Y, Kouyama JI, Naiki K, Yamaba S, Fuchigami A, Saito Y, Shiokawa K, Fujii Y, Uchiya H, Nakazawa M, Ando S, Nakao M, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Mochida S. Retreatment with sofosbuvir/ledipasvir with or without lead-in interferon-β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy. Hepatol Res 2018;48:233-43. [PMID: 28884930 DOI: 10.1111/hepr.12980] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
155 Kichatova VS, Kyuregyan KK, Soboleva NV, Karlsen AA, Isaeva OV, Isaguliants MG, Mikhailov MI. Frequency of Interferon-Resistance Conferring Substitutions in Amino Acid Positions 70 and 91 of Core Protein of the Russian HCV 1b Isolates Analyzed in the T-Cell Epitopic Context. J Immunol Res 2018;2018:7685371. [PMID: 29577052 DOI: 10.1155/2018/7685371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
156 El-Shamy A, Shoji I, Saito T, Watanabe H, Ide YH, Deng L, Kawata S, Hotta H. Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy. Microbiol Immunol. 2011;55:418-426. [PMID: 21371092 DOI: 10.1111/j.1348-0421.2011.00331.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
157 Watanabe T, Konishi I, Shigematsu S, Uesugi K, Joko K, Seike H, Okada S, Miyaoka H, Nakanishi S, Abe M, Matsuura B, Michitaka K, Horiike N, Hiasa Y, Onji M. Sustained virological response of patients with hepatitis C virus genotype 2 depends on pegylated interferon compliance: PEG IFN compliance in HCV genotype 2. Hepatology Research 2011;41:722-30. [DOI: 10.1111/j.1872-034x.2011.00816.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
158 Toyoda H, Kumada T, Shimada N, Takaguchi K, Ide T, Sata M, Ginba H, Matsuyama K, Izumi N. Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin. BMC Infect Dis 2012;12:324. [PMID: 23181537 DOI: 10.1186/1471-2334-12-324] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
159 Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M. Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis. Hepatology. 2012;56:2134-2141. [PMID: 22806754 DOI: 10.1002/hep.25949] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
160 Mizokami M. Discovery of critical host factor, IL-28B, associated with response to hepatitis C virus treatment. J Gastroenterol Hepatol. 2012;27:425-429. [PMID: 22168813 DOI: 10.1111/j.1440-1746.2011.07054.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
161 Watanabe S, Enomoto N, Koike K, Izumi N, Takikawa H, Hashimoto E, Moriyasu F, Kumada H, Imawari M; PERFECT Study Group. Prolonged treatment with pegylated interferon α 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan. Hepatology Research 2010;40:135-44. [DOI: 10.1111/j.1872-034x.2009.00567.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
162 Arase Y, Kawamura Y, Suzuki Y, Suzuki F, Akuta N, Matsumoto N, Seko Y, Sezaki H, Kobayashi M, Hosaka T. Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load. Hepatol Res. 2012;42:949-957. [PMID: 22612669 DOI: 10.1111/j.1872-034x.2012.01008.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
163 Noguchi T, Tamori A, Ogura N, Hori Y, Ikeda S, Nishiguchi S. Investigation of Interferon-α Response by a Single Amino Acid Substitution of Nonstructural Protein 5A in Hepatitis C Virus-Infected Patients. Journal of Interferon & Cytokine Research 2011;31:589-99. [DOI: 10.1089/jir.2010.0128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
164 Kuga C, Enomoto H, Aizawa N, Takashima T, Ikeda N, Ishii A, Sakai Y, Iwata Y, Tanaka H, Saito M. Anti-interferon-α neutralizing antibody induced telaprevir resistance under the interferon-α plus telaprevir treatment in vitro. Biochem Biophys Res Commun. 2014;454:453-458. [PMID: 25450683 DOI: 10.1016/j.bbrc.2014.10.111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
165 Maekawa S, Sakamoto M, Miura M, Kadokura M, Sueki R, Komase K, Shindo H, Komatsu N, Shindo K, Kanayama A. Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection. Hepatology. 2012;56:1611-1621. [PMID: 22577043 DOI: 10.1002/hep.25826] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
166 Akuta N, Suzuki F, Fukushima T, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M. Prediction of treatment efficacy and telaprevir-resistant variants after triple therapy in patients infected with hepatitis C virus genotype 1. J Clin Microbiol. 2013;51:2862-2868. [PMID: 23784126 DOI: 10.1128/jcm.01129-13] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
167 Tamai H, Shimizu R, Shingaki N, Mori Y, Maeshima S, Nuta J, Maeda Y, Moribata K, Muraki Y, Deguchi H, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M. Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks. Hepat Res Treat 2014;2014:748935. [PMID: 25328696 DOI: 10.1155/2014/748935] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
168 Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y. Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma. J Med Virol. 2008;80:1354-1362. [PMID: 18551609 DOI: 10.1002/jmv.21202] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
169 Toyoda H, Kumada T. Incidence of hepatocellular carcinoma and response to interferon therapy in HCV-infected patients: effect of factors associated with the therapeutic response and incidence of HCC. Liver Int 2012;32:1029-31. [PMID: 22314231 DOI: 10.1111/j.1478-3231.2012.02763.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
170 Kohjima M, Enjoji M, Yoshimoto T, Yada R, Fujino T, Aoyagi Y, Fukushima N, Fukuizumi K, Harada N, Yada M. Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C. J Med Virol. 2013;85:250-260. [PMID: 23161429 DOI: 10.1002/jmv.23464] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
171 Suhail M, Sohrab SS, Qureshi A, Tarique M, Abdel-Hafiz H, Al-Ghamdi K, Qadri I. Association of HCV mutated proteins and host SNPs in the development of hepatocellular carcinoma. Infect Genet Evol 2018;60:160-72. [PMID: 29501636 DOI: 10.1016/j.meegid.2018.02.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
172 Okamoto K, Akuta N, Kumada H, Kobayashi M, Matsuo Y, Tazawa H. A nucleotide sequence variation detection system for the core region of hepatitis C virus-1b. Journal of Virological Methods 2007;141:1-6. [DOI: 10.1016/j.jviromet.2006.11.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
173 Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. Journal of Hepatology 2007;46:403-10. [DOI: 10.1016/j.jhep.2006.09.019] [Cited by in Crossref: 212] [Cited by in F6Publishing: 196] [Article Influence: 15.1] [Reference Citation Analysis]
174 Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Ikeda K, Kumada H. Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b. J Med Virol 2014;86:1314-22. [PMID: 24797623 DOI: 10.1002/jmv.23966] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
175 Miura M, Maekawa S, Takano S, Komatsu N, Tatsumi A, Asakawa Y, Shindo K, Amemiya F, Nakayama Y, Inoue T. Deep-sequencing analysis of the association between the quasispecies nature of the hepatitis C virus core region and disease progression. J Virol. 2013;87:12541-12551. [PMID: 23946458 DOI: 10.1128/jvi.00826-13] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
176 Hayashi K, Katano Y, Kuzuya T, Tachi Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I. Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin. J Med Virol. 2012;84:438-444. [PMID: 22246829 DOI: 10.1002/jmv.23207] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
177 Matsuura K, Watanabe T, Tanaka Y. Role of IL28B for chronic hepatitis C treatment toward personalized medicine. J Gastroenterol Hepatol. 2014;29:241-249. [PMID: 24325405 DOI: 10.1111/jgh.12475] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
178 Yamagiwa S, Ishikawa T, Waguri N, Sugitani S, Wakabayashi H, Ohkoshi S, Tsukishiro T, Takahashi T, Watanabe T, Terai S. Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C. World J Hepatol 2017; 9(5): 252-262 [PMID: 28261382 DOI: 10.4254/wjh.v9.i5.252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
179 Nakamoto S, Kanda T, Yonemitsu Y, Arai M, Fujiwara K, Fukai K, Kanai F, Imazeki F, Yokosuka O. Quantification of hepatitis C amino acid substitutions 70 and 91 in the core coding region by real-time amplification refractory mutation system reverse transcription-polymerase chain reaction. Scand J Gastroenterol 2009;44:872-7. [PMID: 19424931 DOI: 10.1080/00365520902937362] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
180 Miura M, Maekawa S, Kadokura M, Sueki R, Komase K, Shindo H, Ohmori T, Kanayama A, Shindo K, Amemiya F. Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C. Hepatol Int. 2012;6:386-396. [PMID: 22020823 DOI: 10.1007/s12072-011-9307-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
181 Hu Z, Liu Y, Qiu L, Fan Z, Nie W, Liang S, Jin R. Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy. Virol J 2015;12:220. [PMID: 26684004 DOI: 10.1186/s12985-015-0451-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
182 Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, Sakamoto M. Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy. PLoS One. 2011;6:e24514. [PMID: 21935415 DOI: 10.1371/journal.pone.0024514] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
183 Tadokoro K, Kobayashi M, Suzuki F, Tanaka C, Yamaguchi T, Nagano M, Egashira T, Kumada H. Comparative quantitative analysis of hepatitis C mutations at amino acids 70 and 91 in the core region by the Q-Invader assay. J Virol Methods. 2013;189:221-227. [PMID: 23124003 DOI: 10.1016/j.jviromet.2012.10.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
184 Akkız H, Akgöllü E, Bekar A, Yıldırım S, Sandıkçı M, Ülger Y, Yalınbaş Kaya B, Kuran S, Üsküdar O. Relationship between IL28B gene rs8099917 polymorphism and SVR in Turkish patients with hepatitis C virus genotype 1. Clinics and Research in Hepatology and Gastroenterology 2015;39:711-7. [DOI: 10.1016/j.clinre.2015.02.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
185 Mori N, Imamura M, Kawakami Y, Saneto H, Kawaoka T, Takaki S, Aikata H, Takahashi S, Chayama K. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. J Med Virol. 2009;81:640-649. [PMID: 19235866 DOI: 10.1002/jmv.21438] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
186 Toyoda H, Kumada T, Tada T, Kawaguchi T, Murakami Y, Matsuda F. Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C. J Med Virol 2011;83:1203-11. [PMID: 21567424 DOI: 10.1002/jmv.22092] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
187 Hayes CN, Chayama K. Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses: ISGs in HCV and HBV Infection. J Med Virol 2017;89:388-96. [DOI: 10.1002/jmv.24659] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
188 李沛元, 姚蓝, 郭波, 宋家武. IL-28B基因多态性-丙型肝炎个体化治疗的新起点. 世界华人消化杂志 2012; 20(2): 119-124 [DOI: 10.11569/wcjd.v20.i2.119] [Reference Citation Analysis]
189 Hashimoto Y, Ochi H, Abe H, Hayashida Y, Tsuge M, Mitsui F, Hiraga N, Imamura M, Takahashi S, Nelson Hayes C, Ohishi W, Kubo M, Tsunoda T, Kamatani N, Nakamura Y, Chayama K. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2011;83:981-8. [DOI: 10.1002/jmv.22028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
190 El-Shamy A, Hotta H. Impact of hepatitis C virus heterogeneity on interferon sensitivity: An overview. World J Gastroenterol 2014; 20(24): 7555-7569 [PMID: 24976696 DOI: 10.3748/wjg.v20.i24.7555] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
191 Takeyasu M, Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma. J Med Virol 2012;84:1199-207. [DOI: 10.1002/jmv.23288] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
192 Ogata F, Akuta N, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K, Kumada H. Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens. J Med Virol 2018;90:1087-93. [PMID: 29427443 DOI: 10.1002/jmv.25047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
193 Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, Belle SH, Di Bisceglie AM, Aurora R, Tavis JE. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol. 2007;81:8211-8224. [PMID: 17522222 DOI: 10.1128/jvi.00487-07] [Cited by in Crossref: 92] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
194 Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype. J Gastroenterol Hepatol 2013;28:443-9. [PMID: 23173698 DOI: 10.1111/jgh.12039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
195 Kobayashi M, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Hosaka T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. J Gastroenterol. 2012;47:596-605. [PMID: 22438096 DOI: 10.1007/s00535-012-0531-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
196 Nishikawa H, Enomoto H, Nasu A, Aizawa N, Saito M, Tamori A, Kawada N, Kimura T, Osaki Y, Nishiguchi S. Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy: IP-10 in telaprevir-based triple therapy. Hepatol Res 2014;44:E397-407. [DOI: 10.1111/hepr.12326] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]